Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal treatment duration of olanzapine after remission of a manic or mixed episode
2004-001308-11Phase 4Active
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of olanzapine in bipolar I disorder (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Prevention of relapse assessed by YMRS and HAMD-21 and Hospital admission as part of relapse assessment. Started Mar 2012; status: active.
02
Drugs
olanzapine
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on 2004-001308-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001308-11.